Antimalarial drug resistance has repeatedly frustrated global efforts to limit morbidity and prevent mortality from *Plasmodium falciparum* malaria. Recently, landmark studies conducted in Western Cambodia in patients who had been treated with artemisinin derivatives have reported an alarming delay in parasite clearance[@b1][@b2]. Since then, infections with increasingly delayed clearance were also reported from Western Thailand and it was suggested that this *in vivo* phenotype is genetically determined[@b3]. Because artemisinin-based combination chemotherapies are the backbone of global malaria control programs, this situation constitutes a public health emergency. Historically, Southeast Asia has been the origin of global spread of drug resistance-conferring mutations. The reason for this geographical bias is only partially understood, but ecological, behavioral and biological factors that may play a role include high rates of inbreeding in the mosquito vector, which reduce competition and favor clonal expansion of emerging genetic variants under drug pressure[@b4], indiscriminate use of poor-quality drugs[@b5] and possibly, "hyper-mutant" parasite strains[@b6].

High throughput whole-genome sequencing technology has revolutionized the approach for identifying genetic variants associated with phenotypes of interest in natural populations. We have harnessed this natural genetic strategy for identifying novel candidate genes that modify the susceptibility of *P. falciparum* to antimalarial drugs. We hypothesized that the range of phenotypic variation observed in natural populations of *P. falciparum* is hard-wired to naturally occurring genetic variants, termed 'standing variation', without necessarily reflecting "resistance" as an evolutionary adaptation to selective pressure[@b7][@b8]. Here we present the results of a genome-wide study in 27 isolates of *Plasmodium falciparum* obtained from malaria patients in Kilifi, Kenya.

Results
=======

*In vitro* phenotyping of *P. falciparum* isolates from Kenyan malaria patients
-------------------------------------------------------------------------------

Fully culture adapted *P. falciparum* isolates obtained from pediatric patients enrolled in a clinical trial in Kilifi District, Kenya[@b9] were subjected to independently repeated growth inhibition assays to obtain reproducible drug sensitivity phenotypes (expressed as half-maximal inhibitory concentration; IC~50~). We focused on a panel of 8 common antimalarial drugs based on their importance as former (chloroquine, CQ; pyrimethamine, PM; and desethyl-amodiaquine, DEAQ) and current (dihydroartemisinin, DHA; lumefantrine, LM; piperaquine, PPQ; and quinine, QN) first or second line antimalarial treatments in Kenya. Mefloquine (MQ) was added because of its global importance for treating and preventing malaria. The median IC~50~ values (range) were 37 nM (12--310) for CQ; 22 μM (3--70) for PM; 22 nM (7--120) for DEAQ; 2 nM (0.5--4) for DHA; 17 nM (4--85) for LM; 49 nM (24--122) for PPQ; 60 nM (12--140) for QN; and 29 nM (7--99) for MQ. The intra-sample correlation between IC~50~ assay replicates (a measure of reproducibility) was high (median: 0.97, range: 0.90--0.99). The median correlation between drug assays was 0.18, and varied between 0.01 (lumefantrine and quinine) and 0.76 (LM and MQ) (see [Figure 1](#f1){ref-type="fig"} for a summary of the assays). The observed pattern of correlations ([Fig. 1](#f1){ref-type="fig"}) was consistent with previously published data (e.g., DHA and LM, 0.46 and DHA and MQ, 0.58)[@b10][@b11]. We did not classify isolates into sensitive and resistant categories for several reasons. First, there is no general consensus on *in vitro* cutoff values and their relevance for *in vivo* resistance can be obscured by unrelated parameters (primarily, of pharmacokinetic and immunological nature). For the artemisinin class of drugs, only recently studies started to address the relationship between specialized novel *in vitro* assays (not done here) and the delayed parasite clearance phenotype observed *in vivo*[@b12]. Secondly, there is increased statistical power in using quantitative, as opposed to qualitative, data for association analyses.

Whole genome sequence analysis
------------------------------

The sequencing technology yielded a median of 18.7 (range: 8.6--38.8) million 54--76 base-pair reads across the 27 samples. Mapping uniquely the reads to the reference 3D7 genome[@b13] yielded a genome-wide average of 57.3-fold coverage, and a median of 86.2% of the genome being covered, 69.6% to at least a five-fold coverage level. The average number of allelic differences to 3D7 (at an error rate of 1 per 1000) was 8899/strain, and across all samples 182,357 positions were identified, leading to 75,471 high quality bi-allelic SNPs (with \<10% missing alleles per position among all samples, minor allele frequency of 5%) carried forward for further analysis. The vast majority of SNPs (66,966, 88.7%) contained no heterozygous genotype calls. Overall, only 0.6% of genotype calls were heterozygous, potentially indicative that few infections/isolates were multi-clonal. Using a principal component analysis on the SNPs, there was no evidence of any samples being continental outliers or identical genetically (for instance, due to potential contamination) ([Fig. S1](#s1){ref-type="supplementary-material"}).

Association analysis
--------------------

Because of the observed deviation from a normal distribution of *in vitro* responses ([Fig. 1](#f1){ref-type="fig"}) we applied a conservative non-parametric tests for the phenotype-genotype association analysis ([Table 1](#t1){ref-type="table"}, [Table S1](#s1){ref-type="supplementary-material"}). We observed ten-fold differences in the range of IC~50~ values (the 'effect size') for chloroquine and DHA ([Figure 1](#f1){ref-type="fig"}), with standard deviations of measurements of at most 30% of values[@b14]. With a sample size of 27, we would expect to have over 95% power (5% type I error) to detect a 3-fold difference using a Wilcoxon text at a minimum allele frequency of 7.4% (2/27). Similarly, we are able to detect a two-fold difference at a minimum allele frequency of 11.1% (3/27).

In a first analysis, we sought to internally validate our approach by using chloroquine resistance as reference. Indeed, we identified *MAL7P1.27*, which encodes the chloroquine resistance transporter (*CRT*), as the most significant association hit covered by four coding SNPs (P ≤ 10^−4^) on chromosome 7 ([Table S1](#s1){ref-type="supplementary-material"}, [Fig. S1](#s1){ref-type="supplementary-material"}).

Based on these reassuring results, we instituted a screen for associations with susceptibilities to 8 drugs. The following number of SNPs (genes, intergenic positions not listed) were lower than the computed significance threshold of 7 × 10^−4^ ([Table 1](#t1){ref-type="table"}): (i) 2 hits for PPQ (*PF07_0019*), (ii) 1 hit for LM (0), 5 hits for DHA (*PFA0220w, PFB0560w, PFA0630c, PFF1445w*), (iii) 21 hits for CQ 21 (*MAL7P1.108 MAL7P1.27, PF11_0127, PFA0665w, PFC0690c, PFF0475w, PFI1560c, PFL2270w*), (iv) 14 hits for QN (*MAL13P1.333, PF13_02*[@b15]*01 PF14_0215, PF14_0647, PF14_0726, PFD0700c, PFL0135w*), (v) 1 hit for MQ (*PFE1330c*), (vi) 17 hits for PM (*PF07_0107, PF10_0356, PF11_0271, PF11_0334, PFA0555c, PFA0650w, PFB0405w, PFC0705c, PFC0820w, PFC0970w, PFF0670w*) and (vii) 19 for DEAQ (*MAL8P1.157, PF07_0016, PF11_0327, PF11_0388, PF13_0104, PF13_0254, PFA0150c, PFA0510w*). These hits were confirmed using the Spearman's rank approach ([Table S1](#s1){ref-type="supplementary-material"}). Of particular interest were two SNPs associated with DHA susceptibility on chromosome 13 at nucleotide positions 717855 and 1644675 (Wilcoxon, P = 5 × 10^−5^; Spearman's rank, P = 5 × 10^−5^; [Tables 1](#t1){ref-type="table"}, [S1](#s1){ref-type="supplementary-material"}) that represented the most significant hits across all comparisons. Equally of major interest was a coding SNP (C-\>G; K873R) in *PFA0220w* that was found to be associated with DHA sensitivity. A homolog of this gene was originally identified in *P. chabaudi* as determinant of parasite survival in artemisinin drug treated murine hosts (*PCHAS_020720*, encoding a putative deubiquitinase)[@b15]. Another SNP associated with DHA response implicated *PFB0630c*, a gene that has homology to stress-responsive RNA polymerase II-binding proteins[@b16]. There was some evidence for SNP associations in other candidate regions for the other tested drugs, including *DHFR* (PM, *PFD0830w*, P = 0.0173), *MDR1* (MQ, *PFE1150w*, P = 0.0038), *MRP2* (QN, *PFL1410c*, P = 0.0052), *NHE-1* (QN, *PF13_0019*, P = 0.0033), but these did not exceed the stringent significance threshold ([Table S2](#s1){ref-type="supplementary-material"}). Among the collected samples we did not find evidence of the *MDR1* gene (*PFE1150w*) amplification, which had been found to be associated with MQ resistance[@b17]. Because it has recently been suggested that only a very limited number of genes may be involved in modifying drug susceptibility[@b18], we studied the specificity of SNP hits for a given drug by querying the database for significant association with other drugs ([Table S2](#s1){ref-type="supplementary-material"}). Not a single SNP hit was associated with more than one drug when using a moderate significance threshold for secondary associations ([Table S2](#s1){ref-type="supplementary-material"}). There was a single hit for lumefantrine (*MAL7P1.30*) that occurred in a region highlighted by several hits for CQ on chromosome 7 ([Table S2](#s1){ref-type="supplementary-material"}). The top 0.05% correlations (corresponding to either, rho \> 0.68 or p \< 0.0007) were retained from [Table S1](#s1){ref-type="supplementary-material"}.

Signatures of recent positive selection
---------------------------------------

Drug pressure is a powerful selective force in natural *Plasmodium* populations[@b19][@b20]. It is well understood that positive selection acting on a beneficial trait gives rise to characteristic regions of low genetic diversity surrounding the causal genetic variant(s) due to the preservation of linkage disequilibrium during meiosis (recombination in regions of 17 kb is estimated to occur only in 1% of meioses during this life-cycle bottleneck in the mosquito mid-gut[@b21]). Here, we sought to identify regions of the genome under recent positive selection, as these may represent signatures of adaptation to drug pressure ([Table 2](#t2){ref-type="table"}, [](#f2){ref-type="fig"}[Figure 3](#f3){ref-type="fig"}). To achieve this, we calculated the integrated haplotype score (iHS) for all 75 k SNPs across the whole genome, applying a stringent threshold (iHS \> 3.6, top 0.2%). Again in an initial validation of the analytical approach using the established chloroquine resistance locus *CRT* as positive control, we found a large 45 kb region surrounding *CRT* that was characterized by lower than expected genetic diversity (*PF07_0028* (2), *PF07_0035* (6), *PF07_0036* (1), *PF07_0037 (1)*, *MAL7P1.30* (1), and *PF07_0042* (2)).

We identified the following genes located in such 'valleys' of low diversity (number of SNP hits) in the genome-wide scan: (i) *PFA0205w* (2), (ii) *PFA0220w* (*UBP1*-homologue) (1), (iii) *PFC0935c* (2) (coding for a putative N-acetylglucosamine-1-phosphate transferase), (iv) *PFC0940c* (1), (v) *PFE1210c* (1), (vi) *PFF1350c* (13) (coding for a putative member of the acetyl-CoA synthetase family[@b22]), (vii) *PFF1365c* (2), (viii) *PFF1485w* (1), (ix) *PF07_0004* (3), (x) *MAL7P1.207* (2), (xi) *PF07_0066*, (xii) a 50 kb region downstream of *PfDHPS* (*MAL8P1.112 (1)*, *MAL8P1.113* (5), *PF08_0100* (1), (xiii) *PFI0805w* (1), (xiv) *PF10_0015* (2), (xv) *PF11_0074*, (xvi) *PF11_0420* (2), (xvii) *PFL1525c* (1), (xviii) *PFL1835w* (1), (xiix) *PF14_0726* (3).

The \|iHS\| method may be insensitive to detect signatures of positive selection for polymorphisms that have reached fixation, we therefore proceeded to apply the cross-population extended haplotype score (XP-EHH) approach to compare the Kenyan to other *P. falciparum* populations (Burkina Faso, Cambodia, Mali, Thailand) to identify evidence for positive selection of alleles that have reached or are near fixation in individual populations[@b23]. The analysis confirms selection acting on *PfCRT* across all comparisons, but also at the *PfDHPS* locus across African populations ([Fig. S2](#s1){ref-type="supplementary-material"}).

In our analysis of genomic regions with low diversity, we also found the current vaccine candidates *MSP1* (2), *AMA1* (4) (previously described by Mu et al.[@b24]), and *TRAP* (6). This was a surprising finding because these genes are thought to be targets of protective immunity and are known to contain extensive SNP and/or repeat polymorphisms. To obtain reassurance that our finding did not result from spurious genomic data, we implemented the Tajima's D metric[@b25], an approach for distinguishing between a DNA sequence evolving randomly ("neutrally", values close to zero) and one evolving under a non-random process, including directional selection (low negative values) or balancing selection (high positive values). Indeed when calculating the Tajima's D on a gene-by-gene basis we found 18 loci, including *AMA1*, *MSP3*, *MSP3.8*, *MSP6* vaccine candidates ([Table S3](#s1){ref-type="supplementary-material"}). These results could indicate the co-existence of reverse selective forces on different domains and/or upstream and downstream regulatory elements of the same gene. For instance, purifying selection could act on functional domains such as transmembrane stretches or functional motives while at the same time, diversifying selection acts on immunologically exposed extracellular loops[@b26]. Alternatively, the co-existence of hyper-variable 'islands' within regions of lower than expected diversity may point to a previously unrecognized feature of chromosome biology that is providing a pathway for diversification at amino acid residues or entire domains exposed to adaptive immune responses.

Association and selection by gene
---------------------------------

Recent positive selection of survival-promoting genotypes, such as drug resistance-conferring mutations, should be detectable both by genotype-phenotype association *and* by 'phenotype-free' analysis of genomic structures (see above section on signatures of recent positive selection) as long as (i) selective pressure has had sufficient time to shape evolution or on the opposite end of the evolutionary time scale, (i) the causal genetic variant has not yet reached fixation in the population (i.e., close to 100% prevalence). We used a simple composite score (termed 'total evidence score', TES) calculated as the sum of the negative decadic logarithm (−log~10~) of the P-value for association and the iHS score for unusually large haplotypes for each of the 75,471 high-quality bi-allelic SNPs ([Figure 4](#f4){ref-type="fig"} and [Table S4](#s1){ref-type="supplementary-material"}). Among the top twenty highest ranked SNPs, we found *CRT* (MAL7P1.27), *Cg1* (immediately downstream of *CRT*), and *UBP1.* Of the 44 genes (1.7% of 2591 passing QC) identified by selection or association ([Table S4](#s1){ref-type="supplementary-material"}), only *UBP1*, *CRT* and surrounding loci (PF07_0035), and *PF14_0726* gene regions were identified by both approaches, providing stronger evidence for their role in modulating drug sensitivity. The biological relevance of a modest correlation between association P-values and selection tests (Spearman's correlation 0.41) at a gene level in entire *P. falciparum* genomes is not clear and it may be an artifact stemming from limits to attain significance with low frequency variants in both tests ([Fig. 4](#f4){ref-type="fig"}).

The collected samples were all resistant to pyrimethamine, and there is some evidence of a selective sweeps within 50 kb of the *DHFR* gene and in the 3' region of *DHPS* (which encodes the target of sulfadoxine, involved in the combination therapy with pyrimethamine). The iHS metric is powered to detect sweeps only at intermediate frequency and prior to fixation. This could explain the failure to detect a stronger signal in our samples, all of which were resistant to pyrimethamine *in vitro* and carried the resistance-conferring gatekeeper mutation at codon position 108 (S108N).

Discussion
==========

The identification of loci associated with malarial drug resistance has the potential to support disease surveillance systems and provide public health bodies with the information needed to deliver effective interventions. Here we studied associations between (i) whole-genome sequence variation at single-nucleotide resolution obtained through next-generation sequencing technology and (ii) robust drug susceptibility phenotypes obtained through repeat *in vitro* experiments with the aim to discover novel genes or genomic regions that modify drug susceptibility in 27 isolates of *P. falciparum* collected from Kenyan patients with malaria.

The power of our approach could be demonstrated in an initial proof-of-principle screen for chloroquine resistance-associated genes. The most significant association was found for the *CRT* gene that encodes the well-characterized chloroquine resistance transporter[@b27][@b28]. When extending the analysis to seven important antimalarial drugs, including dihydroartemisinin as both active metabolite and component of the current front-line artemisinin-based combination therapies, we identified several additional loci that were strongly associated with drug response phenotypes ([Table 1](#t1){ref-type="table"} and [Fig. 2A--H](#f2){ref-type="fig"}). Because of the urgency of the artemisinin resistance problem[@b1][@b2][@b3], we focused on specific hits associated with the dihydroartemisinin response phenotype. We could confirm the previously reported association with *PFA0220w*, a homologue of *UBP1* previously identified in a rodent malaria model and coding for a putative de-ubiquitinating protein[@b15][@b29], and we identified three novel candidate genes (*PFB0560w*, *PFB0630c*, *PFF0445w*). Of note, our screen also identified a SNP (MAL13-1644675) located in a 35-kb segment on chromosome 13 that was recently linked to delayed *in vivo* clearance in *P. falciparum* infections from Western Thailand[@b30]. PFB0630c shares homology with the human RPAP2 protein and the yeast Rtr1 protein[@b16] with putative regulatory roles in RNA polymerase II function. This may be of interest in the light of the reported differential expression pattern observed in isolates obtained from *P. falciparum* infections with delayed *in vivo* responses in Cambodia[@b31]. PFB0560w and PFF0445w are conserved *Plasmodium* protein coding genes with no assigned putative functions. PFF0445w had previously been reported to be up-regulated in response to artemisinin pressure *in vitro* in a comparative proteomics study[@b32]. The functional relevance of the chromosome 13 hit (MAL13-1644675; correlation rho = 0.7; P = 0.001), centered between the predicted open reading frames MAL13P1.211 (−1 kb, coding for a hypothetical protein with no predicted function) and PF13_0226 (1.7 kp, predicted to code for an inner membrane complex (IMC) protein) is not known.

We also screened for evidence of recent positive selection in the genomes of our samples. Of particular interest was a strong signal surrounding *PFA0220w* (*UBP1*-homologue) ([Fig. S1](#s1){ref-type="supplementary-material"}). However, we did not detect a similar selection signal for MAL13-1644675 in a 35-kb segment on chromosome 13 that was recently linked to delayed *in vivo* clearance in *P. falciparum* infections from Western Thailand[@b30]. The fact that our screen identified an isolated association at this locus without a signal for recent positive selection may be explained by the evolutionary time point of sampling: artemisinin-based combination therapy was introduced as first-line treatment only 2--3 years before sampling started[@b33]. This hypothesis is supported by evidence for the chloroquine resistance gene *CRT* where both association and signature of selection are present in our data, most likely as a result of longstanding drug pressure[@b19][@b34]. The absence of significantly delayed *P. falciparum* infections in Kilifi after artemisinin treatment despite the moderate allele frequency of MAL13-1644675 in the local parasite population suggests that this, or yet unknown causal, genetic variants in this region on chromosome 13 are required but not sufficient for full blown *in vivo* artemisinin tolerance. Of note, a genome-wide analysis for associations of genotypes with the rate of parasite clearance after treatment with artemisinin-based combinations in patients who donated the *P. falciparum* isolates for this study (presence or absence of microscopically detectable blood stage parasites on day 2[@b9]) did not reveal significant signals ([Fig. S2](#s1){ref-type="supplementary-material"}).

In this study we used a panel of 8 commonly used antimalarial drugs to determine robust chemosensitivity phenotypes. This focus on *in vitro* data was motivated by a lack of correlation between the reported delayed *in vivo* response to artemisinins and the *in vitro* phenotype in most[@b1][@b9], if not all[@b2], studies. Whilst an *in vivo* phenotype would have been preferred, these phenotypes are difficult to measure, and the outcome can be confounded by host genetic, immunity and intra-assay variation. In contrast, the IC~50~ values measured in 27 *P. falciparum* isolates obtained from pediatric patients in Kilifi District on the Kenyan Coast exhibited substantial phenotypic variation (mean \>10-fold; [Fig. 1](#f1){ref-type="fig"}) and a high degree of inter-assay reproducibility. The observed pattern of correlations between drug responses was also consistent with previously published data, reinforcing the confidence in the accuracy of the phenotypes.

In general, complex genetic traits may involve many genes, each of small effect magnitude. However, drug resistance in *P. falciparum* has been reported as strong single locus effects, with beneficial alleles rapidly going to fixation by selective sweeps leaving characteristic low-diversity 'scars' in the genomes of resistant parasites. In practice, that translates into smaller sample size requirements for detecting selection events, compared to association studies for complex traits[@b35]. To account for the potential number of false positives, we applied stringent quality control on the polymorphisms included, a conservative non-parametric testing and an adjusted statistical significance threshold. Our approach relied on natural variation in the parasite, leading to a set of strong candidates, including hitherto unexpected pathways. For instance, the associations of *TRAP* and of *PF14_0647* (coding for a putative Rab GTPase activator) with sensitivity to quinine (a known ion channel blocker[@b36],) ([Table 1](#t1){ref-type="table"}) may point to a role of membrane-associated trafficking in the mechanism of action of quinine.

Our approach is conceptually similar to a study by Mu et al.[@b24] but with \>20 times higher resolution of genetic variation, and with a focus on a single local parasite population obtained from patients in a well-described cohort[@b9][@b37] to reduce potential confounding by population structure. In contrast to Mu et al.[@b24] we found one gene (*PFA0655w*) to be associated with chloroquine, and not mefloquine or dihydroartemisinin, sensitivity and we failed to find evidence for *MDR1*. Another study by van Tyne et al.[@b38] also reported on a genome-wide association study using an array-based genotyping strategy. There was partial overlap in the drugs used and specifically, we could not confirm a gene (PF14_0654) associated with artemisinin sensitivity, possibly related to a lack of power in our small sample size. A parallel study by Park et al.[@b39] could also confirm the efficiency of massively parallel shot-gun sequencing by employing a related strategy designed to increase the resolution of an initial positive selection-based screen by using association test results[@b39]. In contrast to Park et al., however, we did not assume selection through drug pressure to be driving allele frequencies conferring tolerance to the artemisinins relatively shortly after the introduction of artemisinin-based combination chemotherapies. Consequently, we used genomic signatures of positive selection not as a primary screen but as an additional parameter for identifying genes and/or genomic regions associated with artemisinin response rates through non-parametric genotype-phenotype association tests.

In summary, our study in a limited number of *P. falciparum* isolates has shown that a natural genetics approach powered by whole genome sequencing using new short read technologies can identify novel chemosensitivity-determining genes, applied particularly within a robust genome-wide association and selection setting. These results show promise for geographically focused and timely sequence-based studies as a powerful and efficient tool in future disease surveillance programs. We found substantial overlap with previously reported artemisinin resistance-associated candidate genes and regions (prominently, *PFA0220w*, a *UBP1*-homologue and a 35-kb segment on chromosome 13). Because the studied isolates did not originate from artemisinin resistant infections, we hypothesize that the observed associations indicate standing variation that could serve as substrate for selection under continued drug pressure. It also provides a unique reference for the interpretation of results from resistant infections.

Methods
=======

In vitro phenotypes
-------------------

The study was approved by the National KEMRI Ethical Review Committee, Kenya; the Oxford Tropical Research Ethics Committee, UK; and the Ethics Committee, Heidelberg University School of Medicine, Germany. Parasite isolates were obtained in 2007 to 2008 from patients presenting with uncomplicated episodes of *P. falciparum* malaria before initiation of treatment with an artemisinin-based combination therapy (n = 13) and when patients experienced recurrence of infection during follow-up (n = 14)[@b9]. Cryo-preserved isolates were consecutively thawed and adapted to cell culture conditions. Parasites were cultured in complete medium (RPMI supplemented with L-glutamine, 2% heat-inactivated AB serum, 0.1 mM hypoxanthine, gentamicin, and albumax II) in the presence of O+ or A+ blood at 5% packed cell volume and a gas mixture of 5% CO~2~, 5% O~2~ and 90% N~2~. Growth inhibition of parasite cultures at 0.5% packed cell volume and 0.1% parasitemia was determined on 96-well plates by exposure to serial dilutions of *dihydroartemisinin* (DHA, Sigma), *lumefantrine* (LM, Novartis), *piperaquine* (PPQ, SigmaTau), *chloroquine* (CQ, Sigma), *pyrimethamine* (PM, Sigma), *mefloquine* (MQ, Sigma), *N-desethylamodiaquine* (DEAQ, Sigma) and *quinine* (QN, Sigma). After incubation at 37°C for 72 hours, 20 nM SYBR green in lysis buffer (20 mM Tris at pH 7.5, 5 mM EDTA, 0.008% (wt/vol) saponin, and 0.08% (vol/vol) Triton X-100) (doi:10.1128/AAC.01607-06) was added and fluorescence intensity measured at 20 nm (model, manufacturer). Growth inhibition experiments were repeated at least twice (mean, 3.1). Half-maximal inhibitory concentrations (IC~50~) were estimated by non-linear regression.

Sequencing and genetic variant analysis
---------------------------------------

All samples (n = 27) underwent whole genome sequencing, with 54 or 76-base paired end fragment sizes, using Illumina technology (see[@b40] for a description), and processed as previously described[@b41] to identify variation including SNPs and small insertions and deletions. In brief, we mapped all isolates to the 3D7 (version 3.0) reference genome using *smalt* (5), and called variants using *samtools* (6). Sequence polymorphisms were identified empirically using sequence coverage data as previously described (4). The internal replicability and correlation between *in vitro* phenotypes was assessed using Spearman's correlation. Geographical outliers were identified using a principal component clustering approach applied to multi-continental SNP data ([@b40], Short read archive (SRA) Study ERP000190). The integrated haplotype score (iHS, (12)) method was applied to SNPs data to identify long-range directional selection. The selection metric Tajima's D[@b25] was used for distinguishing between a DNA sequence evolving randomly ("neutrally", values close to 0) and one evolving under a non-random process, including directional selection (low negative values) or balancing selection (high positive values). Because of the non-symmetry of phenotypes, the primary assessment of association between phenotypes and genetic variants (alleles) used Wilcoxon rank tests. A secondary analysis applied Spearman's correlation. A statistical significance cut-off (P = 0.0007, −log10 P = 3.15) was inferred by simulation (phenotype-based permutation) to represent a multiple test adjustment of a nominal 5% error rate. For the final hits, we considered only genomic variants in regions that were unique (calculated by sliding 50 base pairs of contiguous sequence across the reference genome), non-subtelomeric, and not in highly variable gene families (*rifins, surfins, stevors*, and *vars*). Regions for follow-up were compared to publically available sequence data[@b40][@b42]. All raw sequencing data for this work is contained in SRA study ERP000190.
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![Manhattan plots of whole genome association tests.\
X-axis is Chromosomes 1 to 14 in alternating colors; Y-axis is the −log10 p-value from a Wilcoxon test; points in blue indicate P-values less than 0.0007 (above horizontal dashed line); DHA *dihydroartemisinin* (Fig. 2A), LM *lumefantrine* (Fig. 2B), PPQ *piperaquine* (Fig. 2C), CQ *chloroquine* (Fig. 2D)*,* PM *pyrimethamine* (Fig. 2E), MQ *mefloquine* (Fig. 2F), QN *quinine* (Fig. 2G), DEAQ *desethylamodiaquine* (Fig. 2H).](srep03318-f2){#f2}

![Evidence of recent positive selection.\
We used the integrated Haplotype Score (iHS), where points above the horizontal dashed line indicated scores in excess of 3.6; x-axis is Chromosomes 1 to 14 in alternating colors; vertical lines correspond to chromosomal locations of *DHFR*, *MDR1*, and *CRT*, *DHPS*, respectively (left to right). Larger sized points indicate significant results in unique, non-telomeric and non-highly variable gene regions.](srep03318-f3){#f3}

![Scatter plot of evidence scores from genotype-phenotype association and genomic structure analyses.\
Values of iHS or −log~10~ P-value from association testing are presented, with the gene names that exceed thresholds (blue: iHS \> 3.6 or p \< 0.0007; red: iHS \> 3 or p \< 0.001). The Spearman's correlation is 0.417 (P \< 0.00001).](srep03318-f4){#f4}

###### Association hits[\*](#t1-fn1){ref-type="fn"}

  Drug         Chr       Position        Gene        Non-ref AF     P-value
  --------- ---------- ------------ --------------- ------------ --------------
  PPQ          MAL2       846411          \-           0.400        0.000175
  PPQ          MAL7       294258       PF07_0019       0.727        0.000467
  LM          MAL12       58573           \-           0.591        0.000555
  **DHA**    **MAL1**   **195090**   **PFA0220w**    **0.182**    **0.000273**
  DHA         MAL13       717855          \-           0.300        0.000052
  DHA          MAL2       514461       PFB0560w        0.227        0.000152
  DHA          MAL2       564143       PFB0630c        0.706        0.000323
  DHA          MAL6       377293       PFF0445w        0.682        0.000528
  CQ           MAL1       535243       PFA0665w        0.300        0.000361
  CQ          MAL11       466177       PF11_0127       0.714        0.000258
  CQ          MAL11      1984983          \-           0.810        0.000334
  CQ          MAL12       58558           \-           0.421        0.000185
  CQ          MAL12       58573           \-           0.591        0.000555
  CQ          MAL12      1952993       PFL2270w        0.227        0.000532
  CQ          MAL12      1958385          \-           0.200        0.000413
  CQ          MAL14      1724141          \-           0.421        0.000027
  CQ           MAL3       638508       PFC0690c        0.182        0.000547
  CQ           MAL6       408695       PFF0475w        0.773        0.000304
  CQ           MAL7       446872          \-           0.545        0.000300
  CQ           MAL7       447960          \-           0.737        0.000172
  **CQ**     **MAL7**   **459785**   **MAL7P1.27**   **0.524**    **0.000108**
  **CQ**     **MAL7**   **460214**   **MAL7P1.27**   **0.500**    **0.000054**
  **CQ**     **MAL7**   **461216**   **MAL7P1.27**   **0.500**    **0.000054**
  **CQ**     **MAL7**   **461609**   **MAL7P1.27**   **0.524**    **0.000108**
  CQ           MAL7       462908          \-           0.500        0.000288
  CQ           MAL7       952716      MAL7P1.108       0.682        0.000352
  CQ           MAL9       705210          \-           0.350        0.000310
  CQ           MAL9      1280862       PFI1560c        0.682        0.000352
  CQ           MAL9      1280868       PFI1560c        0.682        0.000352
  QN          MAL12       158431       PFL0135w        0.682        0.000528
  QN          MAL13       103008       PF13_0075       0.318        0.000352
  QN          MAL13       103215       PF13_0075       0.318        0.000352
  QN          MAL13      1466682       PF13_0201       0.364        0.000281
  QN          MAL13      2636505      MAL13P1.333      0.182        0.000273
  QN          MAL14       908234       PF14_0215       0.667        0.000431
  QN          MAL14      2773249       PF14_0647       0.545        0.000300
  QN          MAL14      3121047       PF14_0726       0.550        0.000536
  QN           MAL2       70533           \-           0.250        0.000258
  QN           MAL2       70541           \-           0.250        0.000258
  QN           MAL2       70752           \-           0.250        0.000258
  QN           MAL2       70779           \-           0.250        0.000258
  QN           MAL2       70796           \-           0.250        0.000258
  QN           MAL4       663941       PFD0700c        0.250        0.000258
  QN           MAL6      1287339          \-           0.524        0.000380
  QN           MAL7       574869          \-           0.368        0.000159
  PM           MAL1       177518          \-           0.333        0.000120
  PM           MAL1       442138       PFA0555c        0.286        0.000442
  PM           MAL1       514844       PFA0650w        0.591        0.000004
  PM           MAL1       515098       PFA0650w        0.273        0.000188
  PM          MAL10      1438690       PF10_0356       0.636        0.000281
  PM          MAL11      1020735       PF11_0271       0.636        0.000044
  PM          MAL11      1263782       PF11_0334       0.773        0.000152
  PM          MAL14      2169608          \-           0.250        0.000516
  PM          MAL14      3174785          \-           0.611        0.000440
  PM           MAL2       376222       PFB0405w        0.364        0.000119
  PM           MAL3       651126       PFC0705c        0.591        0.000390
  PM           MAL3       773402       PFC0820w        0.444        0.000548
  PM           MAL3       921578       PFC0970w        0.727        0.000509
  PM           MAL4      1134664          \-           0.227        0.000532
  PM           MAL4      1134707          \-           0.227        0.000532
  PM           MAL6       575552       PFF0670w        0.318        0.000082
  PM           MAL7      1150591       PF07_0107       0.524        0.000170
  PM           MAL8      1312984       PF08_0002       0.455        0.000300
  DEAQ         MAL1       94893           \-           0.333        0.000431
  DEAQ         MAL1       132613       PFA0150c        0.263        0.000172
  DEAQ         MAL1       403297       PFA0510w        0.182        0.000273
  DEAQ        MAL11       972835          \-           0.545        0.000300
  DEAQ        MAL11      1228186       PF11_0327       0.273        0.000322
  DEAQ        MAL11      1476544       PF11_0388       0.190        0.000334
  DEAQ        MAL13       786385       PF13_0104       0.714        0.000442
  DEAQ        MAL13      1942726       PF13_0254       0.227        0.000152
  DEAQ         MAL2       849778          \-           0.545        0.000207
  DEAQ         MAL2       849818          \-           0.545        0.000207
  DEAQ         MAL2       849823          \-           0.545        0.000207
  DEAQ         MAL2       849837          \-           0.545        0.000207
  DEAQ         MAL2       849896          \-           0.545        0.000207
  DEAQ         MAL3       448562          \-           0.182        0.000273
  DEAQ         MAL4      1136713          \-           0.211        0.000516
  DEAQ         MAL7       254907       PF07_0016       0.227        0.000152
  DEAQ         MAL7       254910       PF07_0016       0.227        0.000152
  DEAQ         MAL8       116107      MAL8P1.157       0.318        0.000352
  DEAQ         MAL8       311608          \-           0.211        0.000516
  DEAQ         MAL8       452012       PF08_0105       0.286        0.000442
  MQ           MAL5      1119259       PFE1330c        0.818        0.000547

\*Wilcoxon non-parametric tests with P \< 0.006 are presented; DHA *dihydroartemisinin*, LM *lumefantrine*, PPQ *piperaquine*, CQ *chloroquine,* PM *pyrimethamine*, MQ *mefloquine*, QN *quinine*, DEAQ *desethylamodiaquine*.

###### Signatures of recent positive selection[\*](#t2-fn1){ref-type="fn"}

  Chromosome     Position    frequency   Allele       Gene          iHS
  ------------ ------------ ----------- -------- -------------- -----------
  MAL1            180291       0.130       A        PFA0205w       3.941
  MAL1            180421       0.717       A        PFA0205w       5.118
  **MAL1**      **192889**   **0.217**   **G**    **PFA0220w**   **3.652**
  MAL2            839683       0.152       A        PFB0935w       3.669
  MAL3            137202       0.870       A        PFC0120w       4.850
  MAL3            884959       0.109       A        PFC0935c       4.843
  MAL3            884962       0.109       A        PFC0935c       4.844
  MAL4            545613       0.109       G        PFD0595w       3.611
  MAL4            611365       0.717       G           \-          3.810
  MAL4            805223       0.065       G        PFD0872w       3.763
  MAL4            994422       0.065       C        PFD1030c       3.982
  MAL4           1148234       0.630       A        PFD1215w       3.958
  MAL4           1148261       0.522       A        PFD1215w       3.692
  MAL5            929750       0.457       G        PFE1120w       3.621
  MAL5           1011110       0.391       C        PFE1210c       3.799
  MAL6           1030822       0.304       G        PFF1225c       3.677
  MAL6           1114493       0.500       A           \-          4.840
  MAL6           1114518       0.543       A           \-          4.154
  MAL6           1114565       0.565       G        PFF1350c       3.973
  MAL6           1114588       0.543       A        PFF1350c       4.201
  MAL6           1114626       0.543       A        PFF1350c       4.201
  MAL6           1114909       0.543       C        PFF1350c       4.201
  MAL6           1114929       0.543       A        PFF1350c       4.201
  MAL6           1114952       0.543       C        PFF1350c       4.201
  MAL6           1115373       0.565       G        PFF1350c       4.846
  MAL6           1115454       0.587       A        PFF1350c       4.802
  MAL6           1116047       0.609       T        PFF1350c       4.853
  MAL6           1116102       0.587       T        PFF1350c       4.786
  MAL6           1116171       0.609       A        PFF1350c       4.730
  MAL6           1116315       0.587       T        PFF1350c       4.821
  MAL6           1117520       0.609       A        PFF1350c       3.786
  MAL6           1128749       0.543       G        PFF1365c       4.064
  MAL6           1132351       0.500       G        PFF1365c       3.959
  MAL6           1268976       0.348       C        PFF1470c       4.036
  MAL6           1271588       0.217       T           \-          4.432
  MAL6           1282898       0.196       T        PFF1485w       4.929
  MAL6           1283740       0.087       T           \-          4.064
  MAL7            430849       0.391       T       PF07_0028       3.763
  MAL7            431906       0.326       C       PF07_0028       3.860
  MAL7            465618       0.870       C       PF07_0035       3.716
  MAL7            465787       0.478       C       PF07_0035       6.267
  MAL7            465791       0.543       A       PF07_0035       4.825
  MAL7            465810       0.587       T       PF07_0035       4.109
  MAL7            466389       0.261       T       PF07_0035       3.963
  MAL7            466988       0.457       T       PF07_0035       4.196
  MAL7            467844       0.370       A       PF07_0036       4.568
  MAL7            476798       0.370       G       PF07_0037       3.732
  MAL7            503466       0.717       G       MAL7P1.30       3.850
  MAL7            520886       0.109       A       PF07_0042       3.626
  MAL7            524323       0.065       T       PF07_0042       4.668
  MAL7            665933       0.152       C           \-          3.713
  MAL7            761532       0.087       G       PF07_0066       4.206
  MAL7           1440395       0.370       C           \-          4.991
  MAL8            469790       0.304       T       PF08_0102       3.840
  MAL8            479954       0.174       C           \-          3.632
  MAL8            491667       0.239       A       MAL8P1.113      5.274
  MAL8            491757       0.217       C       MAL8P1.113      5.665
  MAL8            491831       0.217       G       MAL8P1.113      5.853
  MAL8            491883       0.217       C       MAL8P1.113      5.856
  MAL8            492065       0.587       T       MAL8P1.113      4.366
  MAL8            502511       0.304       A       PF08_0100       4.319
  MAL8            506087       0.283       T       MAL8P1.112      4.061
  MAL9            599641       0.087       G        PFI0685w       3.867
  MAL9            689167       0.891       A        PFI0805w       4.711
  MAL9           1202400       0.065       T        PFI1475w       3.920
  MAL9           1202416       0.065       A        PFI1475w       3.920
  MAL9           1202437       0.065       T        PFI1475w       3.920
  MAL9           1202504       0.065       C        PFI1475w       3.921
  MAL10           61593        0.304       A           \-          4.516
  MAL10           68880        0.065       C       PF10_0015       3.600
  MAL10           68888        0.065       A       PF10_0015       3.660
  MAL10           879301       0.065       G       PF10_0211       3.873
  MAL10          1524131       0.522       A       PF10_0374       3.784
  MAL10          1524172       0.370       T       PF10_0374       3.862
  MAL10          1543093       0.478       A       PF10_0374       4.313
  MAL11           265298       0.065       T       PF11_0074       4.526
  MAL11           681352       0.717       G       PF11_0185       4.136
  MAL11           681360       0.739       G       PF11_0185       4.185
  MAL11          1294582       0.261       A       PF11_0344       6.442
  MAL11          1294701       0.348       C       PF11_0344       4.887
  MAL11          1294706       0.217       C       PF11_0344       6.074
  MAL11          1294751       0.370       A       PF11_0344       4.403
  MAL11          1637771       0.087       T       PF11_0420       3.604
  MAL12           57132        0.109       G           \-          5.100
  MAL12           57138        0.152       T           \-          4.183
  MAL12           95229        0.152       A        PFL0070c       3.764
  MAL12          1579059       0.196       G        PFL1835w       4.093
  MAL13          1465418       0.152       C       PF13_0201       4.118
  MAL13          1465808       0.130       C       PF13_0201       3.624
  MAL13          1465878       0.478       C       PF13_0201       4.519
  MAL13          1465929       0.543       C       PF13_0201       4.213
  MAL13          1465950       0.478       G       PF13_0201       3.931
  MAL13          1466282       0.804       C       PF13_0201       3.900
  MAL13          1466322       0.370       C       PF13_0201       4.446
  MAL13          1466429       0.913       T       PF13_0201       4.973
  MAL13          1466471       0.283       A       PF13_0201       3.921
  MAL14           542167       0.087       A       PF14_0135       4.274
  MAL14          1986848       0.891       T       PF14_0463       3.759
  MAL14          1986850       0.913       T       PF14_0463       3.984
  MAL14          3121318       0.348       T       PF14_0726       3.625
  MAL14          3121371       0.261       C           \-          4.836
  MAL14          3121449       0.174       G       PF14_0726       5.866

\*using the integrated haplotype score (iHS, absolute values \>3.6 are presented).
